GSK rallies Monday, outperforms market
GSK PLC closed 15.77% below its 52-week high of £18.24, which the company reached on May 16th.
ROSEN, NATIONAL TRIAL COUNSEL, Encourages GSK plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - GSK
NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...
Zacks Investment Research on MSN3d
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...
Forbes India4d
Bugworks: Innovating a novel class of antibiotics, cancer drugs
The founders of Bugworks Research are attempting to bring to market a new class of antibiotics--a first in almost half a ...
SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in ...
STAT5d
Warren asks HHS watchdog to investigate GSK over its asthma inhaler maneuvers
After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...
GSK, Pfizer's ViiV Healthcare Shows Strong HIV Viral Suppression In Latest Study
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Le Lézard5d
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...